佰乐博生物蛋白抗体推荐Blinatumomab蛋白抗体，贝林妥欧单抗
一、中文名称：贝林妥欧单抗
二、产品描述：Blinatumomab (Anatumomab) 是一种双特异性单克隆抗体，有两个结合位点，分别是 T 细胞表面的 CD3E 和 B 细胞表面的 CD19。Blinatumomab 可用于急性淋巴细胞白血病的研究。
三、产品详情
货号：DHD10804
表达系统：Mammalian Cells
种属反应性：Human
宿主：Mouse
同种型：(scFv - kappa - heavy)-(scFv - heavy - kappa)
克隆类型：Monoclonal
靶标：CD19, Differentiation antigen CD19, T - cell surface antigen Leu - 12, B - lymphocyte antigen CD19, B - lymphocyte surface antigen B4, T3E, T - cell surface antigen T3/Leu - 4 epsilon chain, CD3e, CD3E, T - cell surface glycoprotein CD3 epsilon chain
浓度：2.27 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS - PAGE.
纯化方式：Purified by Nickel column.
Accession 号：P15391 & P07766
克隆号：Blinatumomab
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：30mM Histidine, pH 5.8, 10% Sucrose, 0.006% Tween 80.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze - thaw cycles. Store at 4°C short term (1 - 2 weeks). Store at - 20°C 12 months. Store at - 80°C long term.
别名：Bispecific, CD19, AMG103, BITE MT - 103, MEDI - 538, MT103, bscCD19xCD3, CAS: 853426 - 35 - 4
四、参考文献：
1. Immunotherapy in Tumors. PMID: 26667979
2. Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort. PMID: 35790143
3. Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance. PMID: 34865945
4. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. PMID: 30238148
5. Novel Treatment Modality for Chimeric Antigen Receptor T-cell Therapy Complications: A Case Report. PMID: 39188428
6. Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study. PMID: 36353258
7. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. PMID: 37187201
8. Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production. PMID: 36200934
9. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. PMID: 37648261
10. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. PMID: 34767461
11. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. PMID: 39218935
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.biolabreagent.com/product/99/4388.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
